Relationship between WBRT total dose, intracranial tumor control, and overall survival in NSCLC patients with brain metastases - a single-center retrospective analysis

Table 5 Prognostic index adjusted Cox models

Prognostic Index			OS		Univariate		Prognostic Index & RT modality^a adjusted
Prognostic Index	n	(%)	MTS	p^b	HR	p^c	HR	p^c	WBRT (Gy)	HR	p^c
RPA class
I	18	(3)	14.1	0.039	0.435	0.032	0.545	0.122	none	1.000	ref.
II	387	(65)	9.5		0.839	0.094	0.703	0.001	< 30	1.412	0.120
III	190	(32)	8.7		1.000	ref.	1.000	ref.	30–39	0.969	0.861
									≥40	0.725	0.019
									≥40 vs. 30–39	0.820	0.270
Lung-GPA score
0–1.0	217	(36)	8.3	0.001	1.000	ref.	1.000	ref.	none	1.000	ref.
1.5–2.0	244	(41)	8.5		0.935	0.528	0.910	0.387	< 30	1.497	0.072
2.5–3.0	117	(20)	13.0		0.615	0.001	0.580	0.000	30–39	0.919	0.644
3.5–4.0	17	(3)	17.2		0.478	0.031	0.511	0.051	≥40	0.731	0.023
									≥40 vs. 30–39	0.864	0.409
Lung-molGPA score
0–1.0	169	(28)	7.0	0.000	1.000	ref.	1.000	ref.	none	1.000	ref.
1.5–2.0	289	(49)	8.9		0.715	0.002	0.629	0.000	< 30	1.673	0.026
2.5–3.0	126	(21)	12.7		0.521	0.000	0.453	0.000	30–39	0.890	0.516
3.5–4.0	11	(2)	25.0		0.259	0.008	0.186	0.001	≥40	0.697	0.009
									≥40 vs. 30–39	0.845	0.342

OS overall survival; RT radiotherapy; MTS median survival time in months; WBRT whole brain radiotherapy; HR hazard ratio; ref. reference; RPA the recursive partitioning analysis; GPA the graded prognostic assessment; Lung-GPA the lung cancer-specific GPA; Lung-molGPA the lung cancer-specific GPA using molecular markers.
^aRT modalities included WBRT, local/boost RT and SRT.
^bfrom the log-rank test.
^cfrom the Cox model analysis

ISSN: 1471-2407